Pulse Biosciences, Inc.
Niv Ad · Biotechnology, Health Care, Medical
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
Key facts
- Headquarters
- Niv Ad
- Employees
- 75
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (PLSE)
- Website
- pulsebiosciences.com
- Company page
Recent activity at Pulse Biosciences, Inc.
- : Pulse Biosciences Enters Clinical Partnership with Clayman Thyroid Center
- : SEC 8-K (8.01): On October 14, 2026, Pulse Biosciences, Inc. announced the establishment of a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. This collaboration aims to explore the clinical utility of Pulse Biosciences' proprietary nPulse Vybrance Percutaneous Electrode System, potentially advancing new therapeutic applications. The partnership could significantly enhance the Company’s clinical reach and reputation in the medical community. Further details are available in the attached press release, indicating the company's strategic focus on innovation in thyroid health management.
- : SEC 8-K (8.01): On October 7, 2026, Pulse Biosciences, Inc. announced the successful achievement of its enrollment target of 164 evaluable patients for the NANOPULSE-AF clinical study, which assesses the nPulse™ Cardiac Catheter System for treating drug-resistant, symptomatic, paroxysmal atrial fibrillation. The study is a prospective, multicenter, non-randomized IDE pivotal clinical investigation, aiming to evaluate the safety and effectiveness of the system. This target was met across 15 clinical sites, with the first patients being treated in April 2026. Evaluations of the primary safety and effectiveness endpoints will occur at 6 and 12 months following the ablation procedures, indicating significant progress in the Company’s clinical research initiatives concerning atrial fibrillation treatment.
- : SEC 8-K (8.01): On September 15, 2026, Pulse Biosciences, Inc. announced the completion of patient enrollment in its PRECISE-BTN clinical study for the nPulse™ Vybrance™ Percutaneous Electrode System designed to treat symptomatic benign thyroid nodules. The project expanded from an initial design of 50 patients to 100 patients at three clinical sites: Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine, all completed within approximately 12 months. The first patient has also finished their final 12-month follow-up visit, indicating significant progress in the study's endpoints which include safety and reduction in nodule volume over designated follow-up periods.
- : SEC 8-K (1.01): On September 15, 2026, Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC. The agreement allows the company to offer and sell shares of its common stock up to an aggregate price of $85,000,000. The sale of these shares is at the company's discretion, and Mizuho will act as the sales agent utilizing commercially reasonable efforts to execute sales in line with the company's specific instructions regarding price, timing, and volume. This transaction is significant as it provides the company with potential capital infusion while not obligating any sale of shares immediately, allowing for flexibility in market conditions.
- : SEC 8-K (1.01): On August 6, 2026, Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC. This agreement allows the Company to offer and sell, at its discretion, up to $75,000,000 worth of its common stock. Mizuho will act as the sales agent and may conduct sales through 'at the market' offerings on The Nasdaq Capital Market. The Company can suspend sales at any time and is not obligated to sell any shares under this agreement. Mizuho will receive up to a 3% commission on gross sales from the shares sold under this agreement, along with reimbursement for specified expenses. A prospectus supplement was filed with the SEC on the same date as the agreement.
- : SEC 8-K (8.01): On July 29, 2026, Pulse Biosciences, Inc. announced that it has surpassed the enrollment midpoint of its NANOPULSE-AF clinical study, which is evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The study commenced in April 2026 and aims to enroll patients at up to 30 sites globally, indicating significant progress in the clinical investigation. This milestone may enhance the company's position in the treatment of atrial fibrillation, reflecting positively on their ongoing research and product development efforts.
- : SEC 8-K (8.01): On July 29, 2026, Pulse Biosciences, Inc. announced that it has surpassed the enrollment midpoint of its NANOPULSE-AF clinical study. This pivotal clinical investigation evaluates the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The study began in April 2026 and is set to enroll patients at up to 30 sites globally, indicating a significant advancement in their research efforts. This milestone reflects the company's commitment to addressing challenging cardiac conditions and may influence future clinical outcomes and potential market opportunities.
- : SEC 8-K (8.01): On June 10, 2026, Pulse Biosciences, Inc. announced via press release its irrevocable election to redeem the outstanding common stock warrants issued on July 3, 2024. This decision pertains to the Warrants issued during the Company’s rights offering under Registration Statement S-3, which allows the Company to redeem these Warrants for $0.01 per underlying share of common stock, provided it gives not less than thirty days' written notice. This strategic move indicates the Company’s desire to manage its capital structure effectively, particularly given the condition that the volume weighted average price of its common stock reaches or exceeds 200% of the exercise price. The Warrants are identified with CUSIP # 74587B143.
- : SEC 8-K (8.01): On June 10, 2026, Pulse Biosciences, Inc. announced the issuance of an irrevocable election to redeem the outstanding common stock warrants issued on July 3, 2024, in connection with its rights offering. The outstanding Warrants will be redeemed for $0.01 per share if the volume weighted average price of the Company's stock meets specific criteria over a set period. This redeeming process is critical as it provides the Company a mechanism to manage its capital structure more effectively, impacting shareholder value and future fundraising. The redemption of the Warrants is scheduled to take place on or before July 13, 2026, and any warrants not exercised by this date will be irrevocably redeemed by the company.
Pulse Biosciences, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2021 | Venture | $50.0M |
| Sep 2017 | Venture | $30.0M |
| Feb 2017 | Venture | $5.0M |
Leadership
- John Sakkis, Director, Talent Acquisition
- Maky Zanganeh, Director
- Thierry Thaure, Director
- Mitchell Levinson, Director
- Robert Greenberg, Director
- Robert Levande, Director
- Darrin Uecker, Executive Officer, Director
- Maky Zanganeh, Director
- Thierry Thaure, Director
- Robert Greenberg, Director
- Mitchell Levinson, Director
- Robert Levande, Director, Promoter
Verified email and direct lines for Pulse Biosciences, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Pulse Biosciences, Inc. in the news
- Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results - Business Wire (May 07, 2026)
- Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026 - Business Wire (Oct 22, 2026)
- Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results - Business Wire (Aug 06, 2026)
- Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study - Business Wire (Jul 29, 2026)
- Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 - Business Wire (Oct 08, 2026)
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire (Oct 09, 2026)
- Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Business Wire (Sep 15, 2026)
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment - Business Wire (Oct 07, 2026)
Companies similar to Pulse Biosciences, Inc.
- Microba Life Sciences Limited · Biotechnology, Health Care, Medical, Therapeutics
- Abivax · Biotechnology, Health Care, Medical, Therapeutics
- ALX Oncology · Biotechnology, Health Care, Medical, Therapeutics
- AvenCell Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- Novadip Biosciences · Biotechnology, Health Care, Medical, Therapeutics
About Pulse Biosciences, Inc.: questions and answers
What does Pulse Biosciences, Inc. do?
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
Where is Pulse Biosciences, Inc. headquartered?
Pulse Biosciences, Inc. is headquartered in Niv Ad.
How many employees does Pulse Biosciences, Inc. have?
Pulse Biosciences, Inc. has about 75 employees.
Has Pulse Biosciences, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Pulse Biosciences, Inc.. The most recent, $50.0M, was in Jul 2021.
What is the latest news on Pulse Biosciences, Inc.?
On Oct 14, 2026, Pulse Biosciences Enters Clinical Partnership with Clayman Thyroid Center
Is Pulse Biosciences, Inc. a public company?
Yes. Pulse Biosciences, Inc. is publicly traded under the ticker PLSE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy